SiBone (NASDAQ:SIBN) Insider Anshul Maheshwari Sells 3,247 Shares of Company Stock

SiBone (NASDAQ:SIBN) insider Anshul Maheshwari sold 3,247 shares of the company’s stock in a transaction dated Wednesday, November 4th. The stock was sold at an average price of $25.00, for a total transaction of $81,175.00. Following the transaction, the insider owned 211,250 shares in the company, valued at approximately $5,281,250. This trade represents a 1.51% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Anshul Maheshwari also recently made the following trade(s):

• On Thursday, October 29th, Anshul Maheshwari sold 3,738 shares of SiBone stock. The shares were sold at an average price of $22.50, for a total transaction of $84,105.00.
• On Monday, October 5th, Anshul Maheshwari sold 1,731 shares of SiBone stock. The stock was sold at an average price of $19.50, for a total transaction of $33,754.50.
• On Friday, October 2nd, Anshul Maheshwari sold 3,318 shares of SiBone stock. The stock was sold at an average price of $18.18, for a total transaction of $60,321.24.
• On Monday, August 24th, Anshul Maheshwari sold 11,636 shares of SiBone stock. The stock was sold at an average price of $20.11, for a total transaction of $233,999.96.
• On Friday, August 21st, Anshul Maheshwari sold 11,228 shares of SiBone stock. The shares were sold at an average price of $20.02, for a total transaction of $224,784.56.
• On Wednesday, August 19th, Anshul Maheshwari sold 5,747 shares of SiBone stock. The shares were sold at an average price of $19.55, for a total transaction of $112,353.85.
• On Monday, August 17th, Anshul Maheshwari sold 4,665 shares of SiBone stock. The shares were sold at an average price of $18.65, for a total transaction of $87,002.25.

SiBone Trading Down 0.1%

SIBN stock traded down $0.03 during trading on Friday, hitting $24.24. The company had a trading volume of 683,472 shares, compared to its average volume of 654,887. The company has a quick ratio of 7.55, a current ratio of 9.15 and a debt-to-equity ratio of 0.20. The firm has a 50-day moving average price of $19.81 and a 200-day moving average price of $16.59. SiBone has a 12 month low of $11.48 and a 12 month high of $25.92. The stock has a market cap of $1.08 billion, a price-to-earnings ratio of -78.19 and a beta of 0.64.

SiBone (NASDAQ:SIBN) last posted its quarterly earnings data on Monday, November 2nd. The company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.13) by $0.05. The firm had revenue of $55.70 million for the quarter, compared to the consensus estimate of $55.31 million. SiBone had a negative return on equity of 7.62% and a negative net margin of 6.20%. As a group, analysts predict that SiBone will post -0.34 earnings per share for the current year.

SiBone News Roundup

Here are the key news stories impacting SiBone this week:

• Positive Sentiment: Quarterly results beat expectations and lifted shares. Si-Bone reported a third-quarter loss of $0.08 per share, narrower than the $0.13 loss analysts expected, while revenue of $55.7 million modestly exceeded estimates. The results were followed by a reported 8.7% stock jump. Article on SIBN’s post-earnings gain
• Positive Sentiment: Analyst support helped drive the stock to a 52-week high. TD Cowen raised its price target to $23 from $20, and UBS raised its target to $26 from $25; both maintained Buy ratings. SIBN reached a 52-week high amid the favorable coverage and earnings momentum. Article on SIBN’s 52-week high and analyst upgrade TD Cowen price-target article UBS price-target article
• Neutral Sentiment: Full-year revenue guidance was reaffirmed. Si-Bone’s 2026 revenue outlook of $231 million to $233 million was broadly in line with analyst expectations, offering limited new information for investors. Si-Bone Q3 results and guidance
• Negative Sentiment: Multiple insiders sold shares. CEO Laura Francis sold 75,000 shares, SVP Michael Pisetsky sold 36,241, Anshul Maheshwari sold 3,247, and director Jeffrey Dunn sold 20,000. The sales may weigh on sentiment, although each retained shares after the transactions. CEO sale filing SVP sale filing Maheshwari sale filing Dunn sale filing

Institutional Investors Weigh In On SiBone

Hedge funds have recently modified their holdings of the business. Versant Capital Management Inc lifted its holdings in shares of SiBone by 102.9% during the 2nd quarter. Versant Capital Management Inc now owns 1,749 shares of the company’s stock valued at $29,000 after purchasing an additional 887 shares in the last quarter. State of Wyoming increased its stake in SiBone by 70.8% during the 1st quarter. State of Wyoming now owns 10,832 shares of the company’s stock worth $137,000 after purchasing an additional 4,490 shares in the last quarter. Inceptionr LLC acquired a new stake in SiBone during the 1st quarter worth approximately $156,000. ADAR1 Capital Management LLC acquired a new stake in SiBone during the 1st quarter worth approximately $159,000. Finally, Elevation Point Wealth Partners LLC bought a new position in SiBone in the first quarter valued at approximately $204,000. Institutional investors and hedge funds own 98.11% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the stock. UBS Group raised their target price on shares of SiBone from $25.00 to $26.00 and gave the company a “buy” rating in a research note on Tuesday. Weiss Ratings upgraded shares of SiBone from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 20th. Wall Street Zen raised shares of SiBone from a “hold” rating to a “buy” rating in a research note on Saturday. Citigroup restated a “market outperform” rating on shares of SiBone in a report on Tuesday. Finally, TD Cowen raised their price objective on shares of SiBone from $20.00 to $23.00 and gave the company a “buy” rating in a research note on Tuesday. Seven equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $25.00.

SiBone Company Profile

SI-BONE, Inc (NASDAQ: SIBN) is a medical device company focused on diagnosing and treating disorders of the sacroiliac joint, which connects the spine to the pelvis. The company develops minimally invasive surgical solutions intended to stabilize the sacroiliac joint and address sacroiliac joint dysfunction and related conditions.

Its product portfolio is centered on the iFuse Implant System, a family of triangular implants designed to be placed across the sacroiliac joint. SI-BONE also offers products such as iFuse-TORQ, a threaded implant system, and iFuse Bedrock Granite, which is designed for sacroiliac joint fusion and pelvic fixation as part of certain spinal procedures.